We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

33 hedge funds and large institutions have $3.05M invested in AYTU BioPharma in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,500% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 1

313% more funds holding

Funds holding: 8 → 33 (+25)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0.19% less ownership

Funds ownership: 0.2% → 0.01% (-0.19%)

63% less capital invested

Capital invested by funds: $8.23M → $3.05M (-$5.18M)

Holders
33
Holders Change
+25
Holders Change %
+312.5%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$460K
2
Renaissance Technologies
Renaissance Technologies
New York
+$295K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$237K
4
SCM
Soleus Capital Management
Connecticut
+$135K
5
Bank of America
Bank of America
North Carolina
+$77.2K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$7.73M
2
SC
Searle & Co
Connecticut
-$112K
3
Morgan Stanley
Morgan Stanley
New York
-$36.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$857K +$460K +2,381 +500%
Renaissance Technologies
2
Renaissance Technologies
New York
$458K +$295K +1,528 New
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$368K +$237K +1,227 New
SC
4
Searle & Co
Connecticut
$234K -$112K -581 -43%
SCM
5
Soleus Capital Management
Connecticut
$209K +$135K +698 New
Bank of America
6
Bank of America
North Carolina
$120K +$77.2K +400 New
ECM
7
ETrade Capital Management
Virginia
$111K +$71.4K +370 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$98K – – –
Goldman Sachs
9
Goldman Sachs
New York
$91K +$58.5K +303 New
Citadel Advisors
10
Citadel Advisors
Florida
$62K +$40.2K +208 New
ECM
11
ExodusPoint Capital Management
New York
$60K +$38.6K +200 New
Victory Capital Management
12
Victory Capital Management
Texas
$48K +$30.7K +159 New
BlackRock
13
BlackRock
New York
$47K +$8.3K +43 +38%
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$40K +$26.3K +136 New
Millennium Management
15
Millennium Management
New York
$38K +$24.3K +126 New
Northern Trust
16
Northern Trust
Illinois
$32K +$10K +52 +98%
HWA
17
HCR Wealth Advisors
California
$30K +$19.3K +100 New
HighTower Advisors
18
HighTower Advisors
Illinois
$25K +$15.8K +82 New
SPC
19
Sigma Planning Corp
Michigan
$23K +$14.9K +77 New
Osaic Holdings
20
Osaic Holdings
Arizona
$20K +$12.6K +65 New
WWM
21
Western Wealth Management
Colorado
$20K +$12.6K +65 New
Cambridge Investment Research Advisors
22
Cambridge Investment Research Advisors
Iowa
$16K +$10.2K +53 New
TCM
23
Traynor Capital Management
Pennsylvania
$15K +$9.65K +50 New
UBS Group
24
UBS Group
Switzerland
$8K +$1.54K +8 +50%
WAP
25
Wealthcare Advisory Partners
Pennsylvania
$6K +$3.86K +20 New
1
2

AYTU Hedge Fund Activity: Q1 2020 in Review

33 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2020, worth a combined $3.05M — down 63% from $8.23M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AYTU positions and 1 closed out — a net gain of 25 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $460K. The largest seller was Armistice Capital, exiting entirely with an estimated $7.73M sold.

  • 33 institutional investors held AYTU BioPharma (AYTU) as of Q1 2020, up from 8 in Q4 2019.
  • Funds reported $3.05M of AYTU BioPharma stock for Q1 2020, down 63% quarter-over-quarter.
  • 26 funds opened new AYTU BioPharma positions in Q1 2020 and 1 closed out, a net change of +25 holders.
  • The largest AYTU BioPharma buyer in Q1 2020 was Vanguard Group, an estimated $460K added.
  • The largest AYTU BioPharma seller in Q1 2020 was Armistice Capital, an estimated $7.73M sold.

Based on aggregated 13F filings for Q1 2020.